| scholarly article | Q13442814 |
| P50 | author | Fei Liu | Q51829849 |
| Terrence D. Mulhern | Q54965497 | ||
| Heung-Chin Cheng | Q43053494 | ||
| P2093 | author name string | Janetta G Culvenor | |
| Ryan D Mills | |||
| P2860 | cites work | GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1 | Q21144926 |
| JNKK1 organizes a MAP kinase module through specific and sequential interactions with upstream and downstream components mediated by its amino-terminal extension | Q22007973 | ||
| Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update | Q22252904 | ||
| Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity | Q22254785 | ||
| LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool | Q24292798 | ||
| MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2 | Q24294736 | ||
| GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease | Q24294785 | ||
| Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers | Q24298093 | ||
| LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis | Q24299176 | ||
| LRRK2 and the stress response: interaction with MKKs and JNK-interacting proteins | Q24300440 | ||
| Kinase activity of mutant LRRK2 mediates neuronal toxicity | Q24303603 | ||
| ARHGEF7 (Beta-PIX) acts as guanine nucleotide exchange factor for leucine-rich repeat kinase 2 | Q24305448 | ||
| Dynamic and static interactions between p120 catenin and E-cadherin regulate the stability of cell-cell adhesion | Q24305940 | ||
| GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2 | Q24306167 | ||
| LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: Impairment of the kinase activity by Parkinson's disease-associated mutations | Q24306239 | ||
| Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant | Q24306788 | ||
| ArfGAP1 Is a GTPase Activating Protein for LRRK2: Reciprocal Regulation of ArfGAP1 by LRRK2 | Q24307742 | ||
| Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications | Q24310608 | ||
| Structural basis of UV DNA-damage recognition by the DDB1-DDB2 complex | Q24310859 | ||
| The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites | Q24313336 | ||
| Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation | Q24316270 | ||
| Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a | Q24316348 | ||
| Neurodegenerative Diseases: Challenges And Opportunities | Q51563574 | ||
| A developmental and molecular analysis of Cdc2 mutations in Drosophila melanogaster | Q52223574 | ||
| Expression, purification and preliminary biochemical and structural characterization of the leucine rich repeat namesake domain of leucine rich repeat kinase 2. | Q54344107 | ||
| Expression, purification and preliminary biochemical studies of the N-terminal domain of leucine-rich repeat kinase 2. | Q54672638 | ||
| LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8. | Q54697490 | ||
| Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays. | Q54781213 | ||
| Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson's disease. | Q54791937 | ||
| Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation | Q57373779 | ||
| Lrrk2 pathogenic substitutions in Parkinson's disease | Q57983291 | ||
| A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease | Q58870346 | ||
| Effector recognition by the small GTP-binding proteins Ras and Ral | Q77863480 | ||
| Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants | Q79555494 | ||
| Independent occurrence of I2020T mutation in the kinase domain of the leucine rich repeat kinase 2 gene in Japanese and German Parkinson's disease families | Q80064503 | ||
| The Parkinson disease gene LRRK2: evolutionary and structural insights | Q80243997 | ||
| Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls | Q80535570 | ||
| Crystal structure of the biglycan dimer and evidence that dimerization is essential for folding and stability of class I small leucine-rich repeat proteoglycans | Q82877699 | ||
| A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan | Q83191880 | ||
| LRRK2 Kinase Regulates Synaptic Morphology through Distinct Substrates at the Presynaptic and Postsynaptic Compartments of theDrosophilaNeuromuscular Junction | Q24316894 | ||
| Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle | Q24317158 | ||
| The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation | Q24318533 | ||
| Interplay of LRRK2 with chaperone-mediated autophagy | Q24322747 | ||
| The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation | Q24324345 | ||
| LRRK2 regulates synaptic vesicle endocytosis | Q24336523 | ||
| Vaccinia-related kinase 2 modulates the stress response to hypoxia mediated by TAK1 | Q24337845 | ||
| Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity | Q24338647 | ||
| 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization | Q24339094 | ||
| Crystal structure of the ankyrin repeat domain of Bcl-3: a unique member of the IkappaB protein family. | Q24535966 | ||
| Crystal structure of a 12 ANK repeat stack from human ankyrinR. | Q24539221 | ||
| Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors | Q24597269 | ||
| Ras-catalyzed hydrolysis of GTP: a new perspective from model studies | Q24630231 | ||
| Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells | Q24651391 | ||
| Autoinhibition by an internal nuclear localization signal revealed by the crystal structure of mammalian importin alpha | Q27617932 | ||
| Crystallographic analysis of the specific yet versatile recognition of distinct nuclear localization signals by karyopherin alpha | Q27622027 | ||
| Crystal structure of a plant ribonuclease, RNase LE | Q27622398 | ||
| RanGAP mediates GTP hydrolysis without an arginine finger | Q27637706 | ||
| The crystal structure of polygalacturonase-inhibiting protein (PGIP), a leucine-rich repeat protein involved in plant defense | Q27641788 | ||
| Structure of a Fbw7-Skp1-cyclin E complex: multisite-phosphorylated substrate recognition by SCF ubiquitin ligases | Q27644446 | ||
| Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase | Q27649733 | ||
| Structural basis of histone H4 recognition by p55 | Q27650473 | ||
| Structure of the Roc–COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase | Q27651307 | ||
| Structural and functional analysis of the interaction between the nucleoporin Nup98 and the mRNA export factor Rae1 | Q27661891 | ||
| Dynamics connect substrate recognition to catalysis in protein kinase A | Q27664877 | ||
| Crystal structures of the armadillo repeat domain of adenomatous polyposis coli and its complex with the tyrosine-rich domain of Sam68 | Q27675061 | ||
| K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions | Q27680654 | ||
| Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations | Q27681111 | ||
| Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins | Q27686798 | ||
| Multiple Ras functions can contribute to mammalian cell transformation | Q34319284 | ||
| Sequences Located within the N-Terminus of the PD-Linked LRRK2 Lead to Increased Aggregation and Attenuation of 6-Hydroxydopamine-Induced Cell Death | Q34428227 | ||
| Ankyrin repeat: a unique motif mediating protein-protein interactions. | Q34592264 | ||
| Expression analysis of Lrrk1, Lrrk2 and Lrrk2 splice variants in mice | Q34723024 | ||
| The leucine-rich repeat structure. | Q34769694 | ||
| Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant | Q35498549 | ||
| Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study | Q35525896 | ||
| Number and brightness analysis of LRRK2 oligomerization in live cells | Q36010883 | ||
| The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity | Q36154267 | ||
| (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD. | Q36223954 | ||
| The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease | Q36325701 | ||
| A Drosophila model for LRRK2-linked parkinsonism | Q36497497 | ||
| Understanding and exploiting substrate recognition by protein kinases | Q36631005 | ||
| Pathogenic mutations in Parkinson disease | Q36770206 | ||
| Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization | Q36780383 | ||
| A helix scaffold for the assembly of active protein kinases | Q36871421 | ||
| LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease | Q36981223 | ||
| Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2. | Q37079316 | ||
| Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease | Q37139305 | ||
| Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease | Q37402225 | ||
| Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. | Q37408628 | ||
| Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization | Q37479332 | ||
| Structural aspects of Rab6-effector complexes | Q37597379 | ||
| Defining the conserved internal architecture of a protein kinase. | Q37625155 | ||
| Through the "gatekeeper door": exploiting the active kinase conformation | Q37650047 | ||
| On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies | Q37856642 | ||
| The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling | Q37872771 | ||
| Structure-Function Relationships of the G Domain, a Canonical Switch Motif | Q37889983 | ||
| Allostery and binding cooperativity of the catalytic subunit of protein kinase A by NMR spectroscopy and molecular dynamics simulations. | Q38011292 | ||
| Analysis of LRRK2 accessory repeat domains: prediction of repeat length, number and sites of Parkinson's disease mutations | Q38044435 | ||
| Phosphorylation of LRRK2: from kinase to substrate | Q38044439 | ||
| Molecular basis for recognition of 2',5'-linked oligoadenylates by the N-terminal ankyrin repeat domain of human ribonuclease L. | Q38306838 | ||
| Structural basis for recognition of 2',5'-linked oligoadenylates by human ribonuclease L. | Q38336230 | ||
| Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S. | Q38520438 | ||
| Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families | Q39095724 | ||
| Regulation and function of protein kinases and phosphatases | Q39802746 | ||
| C-terminal truncation and Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1. | Q40285081 | ||
| Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor | Q41915120 | ||
| Intramolecular activation mechanism of the Dictyostelium LRRK2 homolog Roco protein GbpC. | Q42546197 | ||
| Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities | Q42737973 | ||
| Re-examination of the dimerization state of leucine-rich repeat kinase 2: predominance of the monomeric form | Q42803700 | ||
| LRRK2 guides the actin cytoskeleton at growth cones together with ARHGEF7 and Tropomyosin 4. | Q42812726 | ||
| Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons | Q43120316 | ||
| Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2. | Q43182013 | ||
| Structure of the Roc–COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase | Q46099711 | ||
| Differential effects of familial parkinson mutations in LRRK2 revealed by a systematic analysis of autophosphorylation | Q47835833 | ||
| Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations | Q48252778 | ||
| Analysis of LRRK2 functional domains in nondominant Parkinson disease | Q50279256 | ||
| Structural basis of Rho GTPase-mediated activation of the formin mDia1. | Q50337106 | ||
| A putative Ca2+ and calmodulin-dependent protein kinase required for bacterial and fungal symbioses | Q51036725 | ||
| F-Box Proteins Are Receptors that Recruit Phosphorylated Substrates to the SCF Ubiquitin-Ligase Complex | Q27934075 | ||
| Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology | Q28131833 | ||
| WD-repeat proteins: structure characteristics, biological function, and their involvement in human diseases | Q28216786 | ||
| LRRK2 in Parkinson's disease: protein domains and functional insights | Q28235024 | ||
| Structural principles of leucine-rich repeat (LRR) proteins | Q28241151 | ||
| Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease | Q28292932 | ||
| Structure of the armadillo repeat domain of plakophilin 1 | Q28303634 | ||
| Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif | Q28475942 | ||
| The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling | Q28480459 | ||
| Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease | Q28586694 | ||
| Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S | Q28589899 | ||
| LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity | Q29615144 | ||
| Comparison of ARM and HEAT protein repeats | Q29616046 | ||
| Mechanisms of specificity in protein phosphorylation | Q29617541 | ||
| Kinase activity is required for the toxic effects of mutant LRRK2/dardarin | Q29620478 | ||
| An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. | Q30350674 | ||
| R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. | Q30483115 | ||
| A rapid method for determining protein kinase phosphorylation specificity | Q31155056 | ||
| Identification of a carboxyl-terminal diaphanous-related formin homology protein autoregulatory domain | Q31465756 | ||
| Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. | Q33226010 | ||
| Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data | Q33226682 | ||
| A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan | Q33267533 | ||
| The WD40 domain is required for LRRK2 neurotoxicity | Q33521241 | ||
| GTPase activity plays a key role in the pathobiology of LRRK2. | Q33553458 | ||
| Deletion of the WD40 domain of LRRK2 in Zebrafish causes Parkinsonism-like loss of neurons and locomotive defect | Q33565399 | ||
| Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis | Q33595218 | ||
| Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations | Q33942173 | ||
| Crystal structure of human toll-like receptor 3 (TLR3) ectodomain | Q33987865 | ||
| LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding | Q33999270 | ||
| The importin β binding domain as a master regulator of nucleocytoplasmic transport | Q34024480 | ||
| Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease | Q34112588 | ||
| Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2 | Q34121655 | ||
| A competitive nucleotide binding inhibitor: in vitro characterization of Rab7 GTPase inhibition | Q34225395 | ||
| Roc, a Ras/GTPase domain in complex proteins | Q34280792 | ||
| Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease | Q34300430 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 395-412 | |
| P577 | publication date | 2014-02-24 | |
| P1433 | published in | Human Mutation | Q5937269 |
| P1476 | title | Prediction of the repeat domain structures and impact of parkinsonism-associated variations on structure and function of all functional domains of leucine-rich repeat kinase 2 (LRRK2). | |
| P478 | volume | 35 |
| Q26746897 | Activation Mechanism of LRRK2 and Its Cellular Functions in Parkinson's Disease |
| Q92534986 | Autophagy and LRRK2 in the Aging Brain |
| Q38619109 | Cryo-EM analysis of homodimeric full-length LRRK2 and LRRK1 protein complexes |
| Q58701452 | LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation |
| Q38253871 | LRRK2 pathobiology in Parkinson's disease |
| Q24306357 | LRRK2 transport is regulated by its novel interacting partner Rab32 |
| Q89947277 | Parkinson's disease-associated kinase LRRK2 regulates genes required for cell adhesion, polarization, and chemotaxis in activated murine macrophages |
| Q38213378 | Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation |
| Q42342648 | Synapses in neurodegenerative diseases |
| Q38482479 | The Role of α-Synuclein and LRRK2 in Tau Phosphorylation |
Search more.